eli lilly glp 1 mounjaro endowment Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value Eli Lilly to seek approval

A major shift is coming to the GLP-1 weight loss drug market in 2026 one that could dramatically change who can access these medications, how theyre taken, and how much they cost.

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

New analysis suggests that negotiated pricing still falls short of achieving cost neutrality if GLP-1 drug coverage expands to include weight management.

After a two-year-long shortage, the FDA announced that Eli Lillys GLP-1 drug Mounjaro, and obesity version Zepbound, are back in stock.

for severe obesity and Type 2 diabetes, the entry of low-cost generic versions has led to widespread misuse via online pharmacies and wellness clinics.